A recent clinical study has confirmed the effectiveness of Uromonitor, an innovative urinary biomarker for the surveillance of nonmuscle-invasive bladder cancer (NMIBC). In a cohort of 439 patients with 528 surveillance episodes, the study demonstrated a sensitivity of 87% and specificity of 99%, along with a negative predictive value of 99%. These results confirm Uromonitor®’s eliability in the early detection of recurrences, reducing the need for invasive cystoscopies, improving patient comfort while lowering healthcare costs. Importantly, Uromonitor® maintained consistent performance across all tumor grades and stages, reinforcing its value as a reliable tool for broad clinical application. This landmark study represents the largest single-center validation of its kind and supports the integration of Uromonitor® into standard NMIBC surveillance practices.

Read the Full Article